Answers are grounded in this paper and cite their sources.
Background Systematic investigations on the impact of inhibitors on treatment modalities and overall disease burden in Chinese hemophilia patients based on real-world data remain limited.Research design and methods We analyzed a cross-sectional survey of 543 patients diagnosed with hemophilia in China as of 31 December 2022. Treatment, bleeding, and cost items used recall periods specified in the questionnaire. Group comparisons were descriptive and exploratory.Results The mean age of participants was 26.0 ± 14.8 years, with 99.63% being male. The inhibitor-positive group had a higher proportion of severe hemophilia (93.64% vs. 76.56%, p < 0.001). 54.88% of the patients had disability certificates, and the proportion increased with age. Nearly 90% of the patients older than 30 years had different degrees of disability. The median annual bleeding rate was 20 (IQR 8–36) episodes in inhibitor-positive patients versus 12 (IQR 3–30) in inhibitor-negative patients (p = 0.008). The mean annual prophylaxis infusion frequency was 127.71 ± 54.11 infusions per year (approximately 2.5 infusions per week; median 120, IQR 96–168), with a mean factor consumption per infusion of 21.16 ± 8.28 IU/kg. The average annual per-patient cost was CNY 520,415 ± 773,627, of which the cost of factor therapy was CNY 279,402 ± 627,427.Conclusion In this selected survey sample, inhibitor-positive patients reported a higher median number of bleeding episodes and greater treatment complexity.
No takes yet. Share an insight, caveat, or question.
He et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: